<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26242295</article-id><article-id pub-id-type="pmc">4524369</article-id><article-id pub-id-type="publisher-id">877</article-id><article-id pub-id-type="doi">10.1186/s13063-015-0877-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Luger</surname><given-names>Maria</given-names></name><address><email>maria.luger@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kruschitz</surname><given-names>Renate</given-names></name><address><email>renate.kruschitz@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Marculescu</surname><given-names>Rodrig</given-names></name><address><email>rodrig.marculescu@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Haslacher</surname><given-names>Helmuth</given-names></name><address><email>helmuth.haslacher@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Hoppichler</surname><given-names>Friedrich</given-names></name><address><email>office@sipcan.at</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kallay</surname><given-names>Enik&#x000f6;</given-names></name><address><email>enikoe.kallay@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Kienbacher</surname><given-names>Christian</given-names></name><address><email>christian.a.kienbacher@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Klammer</surname><given-names>Carmen</given-names></name><address><email>n0748048@students.meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kral</surname><given-names>Melanie</given-names></name><address><email>melanie.kral@akhwien.at</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Langer</surname><given-names>Felix</given-names></name><address><email>felix.langer@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Luger</surname><given-names>Eva</given-names></name><address><email>eva.luger@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Prager</surname><given-names>Gerhard</given-names></name><address><email>gerhard.prager@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Trauner</surname><given-names>Michael</given-names></name><address><email>michael.trauner@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Traussnigg</surname><given-names>Stefan</given-names></name><address><email>stefan.traussnigg@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>W&#x000fc;rger</surname><given-names>Tanja</given-names></name><address><email>tanja.wuerger@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Schindler</surname><given-names>Karin</given-names></name><address><email>karin.schindler@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ludvik</surname><given-names>Bernhard</given-names></name><address><email>bernhard.ludvik@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18-20, 1090 Vienna, Austria </aff><aff id="Aff2"><label/>Special Institute for Preventive Cardiology and Nutrition &#x02013; SIPCAN, Guggenbichlerstra&#x000df;e 8/15, 5026 Salzburg, Austria </aff><aff id="Aff3"><label/>Clinical Institute for Medical and Chemical Laboratory Diagnostics, Department of Laboratory Medicine, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18-20, 1090 Vienna, Austria </aff><aff id="Aff4"><label/>Department of Pathophysiology and Allergy Research, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18-20, 1090 Vienna, Austria </aff><aff id="Aff5"><label/>Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18-20, 1090 Vienna, Austria </aff><aff id="Aff6"><label/>Division of General Surgery, Department of Surgery, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18-20, 1090 Vienna, Austria </aff><aff id="Aff7"><label/>Institute of Social Medicine, Centre for Public Health, Medical University of Vienna, Kinderspitalgasse 15/1, 1090 Vienna, Austria </aff><aff id="Aff8"><label/>Department of Pathology, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18-20, 1090 Vienna, Austria </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><elocation-id>328</elocation-id><history><date date-type="received"><day>1</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Luger et al. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Beyond its classical role in calcium homoeostasis and bone metabolism, vitamin D deficiency has been found to be associated with several diseases, including diabetes, non-alcoholic fatty liver disease, and even obesity itself. Importantly, there are limited data on therapeutic strategies for vitamin D deficiency in bariatric patients, and the procedure-specific guidelines may not be sufficient. To improve long-term outcomes, nutritional screening and appropriate supplementation to prevent nutrient deficiencies are urgently needed. Therefore, the aim of this study is to examine effects and safety of a forced dosing regimen of vitamin D versus conventional dose supplementation on vitamin D levels and other parameters in bariatric patients.</p></sec><sec><title>Methods/Design</title><p>The study includes loading plus repeat dosing compared with repeated administration of vitamin D without a loading dose, according to guidelines, in a prospective, double-blind, randomized controlled trial. Up to a triple oral loading dose is given on day 1, then 2 and 4&#x000a0;weeks after surgery (100,000 IU dose each time), followed by an oral maintenance dose (3420&#x000a0;IU/day). The control group (<italic>n</italic>&#x02009;=&#x02009;25) will receive placebo, followed by administration of a standard dose (3420&#x000a0;IU/day). We hypothesize that a significant increase in vitamin D levels will occur in patients in the treatment group (<italic>n</italic>&#x02009;=&#x02009;25) by 24&#x000a0;weeks after surgery. Further measurements are aimed at evaluating changes in inflammation, bone turnover, insulin resistance, blood pressure, liver, mental health, and gut microbiota of patients undergoing omega-loop gastric bypass surgery. Furthermore, possible associations between concentrations of vitamin D, the involved enzymes, or vitamin D receptor in adipose and/or liver tissues will be determined.</p></sec><sec><title>Discussion</title><p>To our knowledge, this trial is the first of its kind with this type of vitamin D supplementation in bariatric patients. Its major strength is the design and implementation of evaluation of influencing factors such as liver function, bone health, inflammation, insulin resistance, blood pressure, symptoms of depression, or microbiota. This alternative vitamin D dosing regimen has the potential to be a safe, fast, evidence-based treatment of vitamin D deficiency in bariatric patients. Owing to the increasing number of bariatric patients, it is also of interest to elucidate the link between obesity and vitamin D.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/show/NCT02092376">NCT02092376</ext-link>. Registered on 17 March 2014.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Bariatric patients</kwd><kwd>Cholecalciferol</kwd><kwd>Obesity</kwd><kwd>Vitamin D</kwd><kwd>Vitamin D supplementation trial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Obesity is a global epidemic [<xref ref-type="bibr" rid="CR1">1</xref>] that is associated with various comorbidities. It is part of the definition of the metabolic syndrome, including arterial hypertension and disturbances in glucose and lipid metabolism, with an inherent risk of development of cardiovascular disease [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. These associated issues and obesity itself contribute to increased morbidity, mortality rates, and health care costs [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p>Weight reduction is not easy to achieve and maintain. Consequently, many individuals, especially those with comorbidities, are referred for bariatric weight loss surgery as a way to treat obesity and (pre)diabetes successfully [<xref ref-type="bibr" rid="CR6">6</xref>]. Bariatric surgery is associated with effective and long-term weight loss in morbidly obese patients and decreases overall mortality [<xref ref-type="bibr" rid="CR7">7</xref>]. At present, there are three categories of bariatric procedures: (1) purely gastric restriction (e.g., gastric banding); (2) gastric restriction with some malabsorption, as represented by the Roux-en-Y (RYGB) or omega-loop gastric bypass (OLGB), reducing the intake and absorption of food [<xref ref-type="bibr" rid="CR8">8</xref>]; and (3) gastric restriction with significant intestinal malabsorption (e.g., biliopancreatic diversion) [<xref ref-type="bibr" rid="CR9">9</xref>]. In general, the more complex the procedure, the better are the results in terms of weight loss [<xref ref-type="bibr" rid="CR10">10</xref>]. Because of this situation and the fact that obesity itself is often accompanied by nutritional deficiencies, bariatric patients often have perioperative nutrient deficiencies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. These deficiencies should be detected and clinically addressed early to avoid postoperative complications. To improve long-term outcomes following bariatric surgery, nutritional screening and prescribing appropriate supplementation to prevent nutrient deficiencies is recommended at an early stage in pre- and postoperative care owing to the malabsorption and insufficient intake. Vitamin D deficiency is common following bariatric surgery and has been reported to occur in 50&#x02013;80&#x000a0;% of bariatric patients [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. There are limited data on how best to treat low vitamin D status in bariatric patients. Procedure-specific guidelines may not be helpful in daily practice, and the updated guidelines have not been evaluated yet [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>Recent studies have shown that vitamin D may have an impact on the prevention of many diseases, including autoimmune disorders, hypertension, cancers, diabetes [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>], depression [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>], and, even more theoretically, probably obesity itself [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p>Obesity is frequently characterized by reduced vitamin D bioavailability, insulin resistance, and a chronic inflammatory response. There is a relationship between serum concentrations of 25-hydroxy-vitamin D (25-OHD) and several circulating inflammatory markers in severely obese individuals [<xref ref-type="bibr" rid="CR31">31</xref>]. This observed relationship between low vitamin D status and obesity may be caused by mechanisms such as sequestration in adipose tissue. The mechanisms underlying the inverse relationship between obesity and vitamin D deficiency are largely unknown. Low serum 25-OHD might contribute to obesity by affecting lipogenesis and/or adipogenesis in the adipose tissue. Interestingly, recent studies [<xref ref-type="bibr" rid="CR32">32</xref>] suggest that the adipose tissue could be a direct target of vitamin D and that the hormone may modulate adipose tissue formation and function [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>Obesity has recently been associated with non-alcoholic fatty liver disease (NAFLD). NAFLD comprises a disease spectrum ranging from relatively benign hepatic steatosis to more severe steatohepatitis, fibrosis, cirrhosis, and ultimately liver cancer [<xref ref-type="bibr" rid="CR38">38</xref>]. It has become the most common form of chronic liver disease in Western countries, with a prevalence approaching 50&#x000a0;% of the population (already 40&#x000a0;% in the European Union) [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. It is estimated that NAFLD will be the number 1 indication for liver transplants in the United States in 2020 [<xref ref-type="bibr" rid="CR41">41</xref>]. Currently, surgical treatment of coexisting NAFLD in morbidly obese patients is an evolving matter of debate [<xref ref-type="bibr" rid="CR42">42</xref>]. A few studies propose that low levels of vitamin D may contribute to the development of NAFLD [<xref ref-type="bibr" rid="CR43">43</xref>]. However, the mechanisms underlying the association of vitamin D and NAFLD are not yet fully understood. Recent animal studies have shown that vitamin D has an important role in the regulation of oxidative stress, the production of proinflammatory cytokines [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], hepatocyte apoptosis [<xref ref-type="bibr" rid="CR46">46</xref>], and even liver fibrosis [<xref ref-type="bibr" rid="CR47">47</xref>]. Furthermore, NAFLD is present in approximately 90&#x000a0;% of bariatric patients [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>], and up to 5&#x000a0;% of these patients may have unsuspected cirrhosis [<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. Because NAFLD is associated with the presence of obesity, glucose and/or lipid disturbances, and arterial hypertension, it is now considered the hepatic manifestation of the metabolic syndrome.</p><p>There are limited data on therapeutic strategies for vitamin D deficiency in bariatric patients, and procedure-specific guidelines may not be very helpful in daily clinical practice. Nevertheless, in the 2013 clinical practice guidelines [<xref ref-type="bibr" rid="CR23">23</xref>], the American Association of Clinical Endocrinologists, the Obesity Society and American Society for Metabolic and Bariatric Surgery recommend a vitamin D supplementation of at least 3000&#x000a0;IU per day and to titrate to the therapeutic 25-OHD level of &#x0003e;75&#x000a0;nmol/L. This recommendation outlines the best evidence level (grade A) [<xref ref-type="bibr" rid="CR23">23</xref>], which is based on a single randomized controlled trial done in the United States [<xref ref-type="bibr" rid="CR53">53</xref>]. In that study, the authors attempted to find the optimal vitamin D treatment dose after surgery. Patients who had undergone RYGB were randomized to three doses of cholecalciferol: 800&#x000a0;IU, 2000&#x000a0;IU, and 5000&#x000a0;IU per day. The authors found that all groups had insufficient vitamin D levels at baseline and after 12&#x000a0;months; sufficient vitamin D concentrations were reached in only 44, 78, and 70&#x000a0;% of the patients in the respective groups [<xref ref-type="bibr" rid="CR53">53</xref>]. Thus, even with very high-dose supplementation, it may be challenging to achieve normal 25-OHD levels in bariatric patients [<xref ref-type="bibr" rid="CR54">54</xref>].</p><p>Vitamin D has multiple physiological functions beyond its classical role in calcium homoeostasis and bone metabolism, and morbidly obese persons have an increased risk for low circulating 25-OHD levels [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>] owing to the storage of vitamin D in adipose tissue [<xref ref-type="bibr" rid="CR55">55</xref>].</p><p>Therefore, randomized controlled trials with vitamin D supplementation, such as the present study (Link between Obesity And Vitamin D in bariatric patients with omega-loop bypass surgery [LOAD]), are needed to establish and further pursue evidence-based and potentially optimal treatment regimens for the increasing number patients with low vitamin D status following bariatric surgery and to define more carefully the impact of specific surgical factors on vitamin D status.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods/Design</title><sec id="Sec3"><title>Overview</title><p>This prospective, double-blind, randomized controlled intervention trial includes administration of a vitamin D loading dose and repeat doses in patients undergoing bariatric surgery. A stratified randomization design is being used to obtain comparable groups to ensure that baseline variables (25-OHD, age, and sex) are evenly distributed between groups. Subjects are randomly assigned to the intervention or control group. In this study, 50 bariatric patients planning to undergo OLGB will be recruited. Over the first month postoperatively (day 1&#x02013;3, weeks 2 and 4), they will receive the loading dose of vitamin D. Afterwards, the maintenance dose will be given up to 24&#x000a0;weeks and until the follow-up visit. An overview of the study design and the assessment points is provided in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The study was approved by the local ethics committee of the Medical University of Vienna (reference number 1899/2013) by the Austrian Competent Authority (reference number LCM-718280-0001), and it complies with the Declaration of Helsinki [<xref ref-type="bibr" rid="CR57">57</xref>]. Furthermore, the protocol was registered at ClinicalTrials.gov (identifier: NCT02092376) and EudraCT (identifier: 2013-003546-16). The study methods are in accordance with the 2010 Consolidated Standards of Reporting Trials (CONSORT) Statement guidelines for reporting randomized trials [<xref ref-type="bibr" rid="CR58">58</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Study design and assessment points</p></caption><graphic xlink:href="13063_2015_877_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Preevaluation</title><p>The methods in this study are built upon a cohort study in which investigators evaluated inter alia the vitamin D status of 50 morbidly obese patients who underwent OLGB [<xref ref-type="bibr" rid="CR54">54</xref>]. The findings of the evaluation illustrated that 96&#x000a0;% had vitamin D deficiency preoperatively and that, after non-standardized vitamin D supplementation, 80&#x000a0;% still had vitamin D deficiency 12&#x000a0;months postoperatively [<xref ref-type="bibr" rid="CR54">54</xref>]. Additionally, there is evidence that, despite forced vitamin D supplementation, some patients are still at risk for increased bone resorption [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. It could be possible that morbidly obese patients might need higher 25-OHD levels to reduce the risk for developing metabolic bone disease, osteoporosis [<xref ref-type="bibr" rid="CR61">61</xref>], or other associated disorders.</p></sec><sec id="Sec5"><title>Study objectives</title><sec id="Sec6"><title>Primary outcome measures</title><p>The primary objective of the present study is to examine whether administration of up to three oral loading doses in the first month postoperatively (day 1 and at weeks 2 and 4), followed by an oral maintenance dose (intervention group) in bariatric patients can significantly increase 25-OHD levels 24&#x000a0;weeks after surgery as compared with a control group receiving placebo followed by the standard daily maintenance dose (control group).</p></sec><sec id="Sec7"><title>Secondary outcome measures</title><p>In further measurements, changes in inflammation, bone turnover, bone mineral density (BMD), insulin resistance, blood pressure, body fat mass, stage of liver stiffness and steatosis, and mental health (improvement of depression) will be investigated. Furthermore, we will assess the adipose depot vitamin D concentrations and expression of enzymes (25-hydroxylases such as CYP27A1, CYP2R1, CYP2J2, CYP3A4, CYP2C11, and CYP27B1, as well as 24-hydroxylase CYP24A1) and vitamin D receptor in subcutaneous tissue (SAT), visceral adipose tissue (VAT), and liver tissue samples collected during surgery. Additionally, the liver tissue samples will be used in addition to the prescribed study-related measures for a histological examination as extended diagnostics for NAFLD or non-alcoholic steatohepatitis and molecular analysis to further evaluate disease specific mechanisms [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p></sec></sec><sec id="Sec8"><title>Recruitment and eligibility</title><p>We are recruiting bariatric patients planning to undergo OLGB and who are in- and/or outpatients in the obesity clinic at the Department of Internal Medicine III or the Department of Surgery at Vienna General Hospital. The inclusion and exclusion criteria are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Inclusion</th><th>Exclusion</th></tr></thead><tbody><tr><td>Men and women ages 18&#x02013;100&#x000a0;years</td><td>Another planned form of bariatric surgery</td></tr><tr><td>Planned OLGB</td><td>Hypercalcemia (calcium &#x0003e;2.63&#x000a0;mmol/L) or hypocalcemia (calcium &#x0003c;1.75&#x000a0;mmol/L)</td></tr><tr><td>25-OHD &#x0003c;75&#x000a0;nmol/L</td><td>Renal insufficiency (creatinine &#x0003e;133&#x000a0;&#x003bc;mol/L or GFR &#x0003c;50&#x000a0;ml/min)</td></tr><tr><td>BMI &#x0003e;40 or &#x02265;35&#x000a0;kg/m<sup>2</sup> with comorbidities</td><td>Primary hyperparathyroidism</td></tr><tr><td>Body weight &#x0003c;150&#x000a0;kg (owing to limitation of DEXA measurement)</td><td>Malignancy</td></tr><tr><td rowspan="5">Capability to consent</td><td>Infection (e.g., HIV)</td></tr><tr><td>Medical conditions requiring daily calcium supplements or antacid use</td></tr><tr><td>Known hypersensitivity to cholecalciferol</td></tr><tr><td>No capability to consent</td></tr><tr><td>Imprisoned persons</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>BMI</italic> body mass index, <italic>DEXA</italic> dual-energy X-ray absorptiometry, <italic>GFR</italic> glomerular filtration rate, <italic>25</italic>-<italic>OHD</italic> 25-hydroxy-vitamin D, <italic>OLGB</italic> omega-loop gastric bypass</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Measurements at several time points</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Name</th><th colspan="2">Screening</th><th colspan="8">Intervention</th><th>Follow-up</th></tr><tr><th/><th>Duration</th><th colspan="2">12 months</th><th colspan="8">6 months</th><th>6 months</th></tr><tr><th>Visits</th><th>Time</th><th/><th>Surgery</th><th>Days 1&#x02013;3</th><th>Wk 2</th><th>Wk 4</th><th>Wk 8</th><th>Wk 12</th><th>Wk 16</th><th>Wk 20</th><th>Wk 24</th><th>Wk 48</th></tr></thead><tbody><tr><td rowspan="4">Anamnesis</td><td>Anamnesis</td><td>X</td><td/><td/><td/><td/><td/><td/><td/><td/><td>X</td><td>X</td></tr><tr><td>Body weight</td><td>X</td><td/><td/><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Anthropometry</td><td>X</td><td/><td/><td/><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Dietary assessment, BDI</td><td>X</td><td/><td/><td/><td>X</td><td/><td>X</td><td/><td/><td>X</td><td>X</td></tr><tr><td>Bone density</td><td>DEXA</td><td>X</td><td/><td/><td/><td/><td/><td/><td/><td/><td>X</td><td>X</td></tr><tr><td rowspan="2">Liver and microbiota</td><td>FibroScan and CAP<sup>TM</sup>
</td><td>X</td><td/><td/><td/><td>X</td><td/><td>X</td><td/><td/><td>X</td><td>X</td></tr><tr><td>Stool samples</td><td>X</td><td/><td/><td/><td>X</td><td/><td>X</td><td/><td/><td>X</td><td>X</td></tr><tr><td>Biopsies</td><td>Liver, SAT, VAT</td><td/><td>X</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="2">Supplementation</td><td>Loading dose</td><td/><td/><td>X</td><td>X</td><td>X</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Maintenance dose</td><td/><td/><td/><td/><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="6">Blood parameter</td><td>Vitamin D</td><td>X</td><td/><td/><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Biochemical</td><td>X</td><td/><td/><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Liver</td><td>X</td><td/><td/><td/><td>X</td><td/><td>X</td><td/><td/><td>X</td><td>X</td></tr><tr><td>Inflammation</td><td>X</td><td/><td/><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Insulin resistance</td><td>X</td><td/><td/><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Bone turnover</td><td>X</td><td/><td/><td/><td>X</td><td/><td>X</td><td/><td/><td>X</td><td>X</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>BDI</italic> Beck Depression Inventory, <italic>CAP</italic> controlled attenuation parameter; <italic>DEXA</italic> dual-energy X-ray absorptiometry, <italic>SAT</italic> subcutaneous adipose tissue, <italic>VAT</italic> visceral adipose tissue</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Sample size calculation</title><p>The study is powered to detect differences among the groups for 24-week serum 25-OHD levels. On basis of the preevaluation (cohort study), the placebo group was conservatively estimated to have an average 24-week 25-OHD level of 50&#x02009;&#x000b1;&#x02009;30&#x000a0;nmol/L. For sample size calculation, the difference in 25-OHD levels between groups will be considered. Given a clinically relevant difference of 30&#x000a0;nmol/L and a standard deviation of 35&#x000a0;nmol/L of the differences, a two-sided significance level of 0.05, a sample size of 22 per group is needed to reach 80&#x000a0;% statistical power. Because imputation for dropouts of 20&#x000a0;% may have some inestimable effect on the assumed standard deviation of the differences, the sample size is increased to 25 per group. To reach this sample size, a total of 50 bariatric patients in the study are needed. The primary endpoint will be analyzed according to the intention-to-treat principle.</p></sec><sec id="Sec10"><title>Randomization</title><p>Subjects are randomly assigned to the intervention or control group, stratified by 25-OHD, age, and sex using the Randomizer for Clinical Trials 1.8.1 online tool [<xref ref-type="bibr" rid="CR64">64</xref>]. Each subject receives an appropriate randomization number. Randomization is carried out after the patient has signed the informed consent form and before undergoing bariatric surgery, right before the baseline assessment. Allocation to the groups is performed with consecutively numbered dark bottles containing either vitamin D<sub>3</sub> (cholecalciferol) or placebo (carrier oil). These allocation bottles are labeled with the randomization number.</p></sec><sec id="Sec11"><title>Intervention</title><sec id="Sec12"><title>Loading dose determination</title><p>A loading dose is an extent of drug or substance designed to fill the central volume of distribution to a concentration that matches the final plateau concentration achieved with the maintenance dose. Consequently, this final plateau could be achieved sooner than the four half-lives required if it is administered only at the maintenance dose rate [<xref ref-type="bibr" rid="CR65">65</xref>]. According to the current guidelines, a minimal daily vitamin D supplementation of at least 3000&#x000a0;IU is recommended [<xref ref-type="bibr" rid="CR23">23</xref>]. To prevent failure of the study due to an insufficient treatment dose, we chose the maximum loading dose for which sufficient safety data are available. The functional half-life for vitamin D<sub>3</sub> in the body is between 2 and 3&#x000a0;months [<xref ref-type="bibr" rid="CR66">66</xref>&#x02013;<xref ref-type="bibr" rid="CR68">68</xref>]. As a result, the loading dose can be calculated as the cumulative maintenance dose that is planned to be given through one functional half-life of vitamin D, as follows:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{Loading}\ \mathrm{dose}=\left(\mathrm{daily}\ \mathrm{maintenance}\ \mathrm{dose}\ \mathrm{of}\ 3420\ \mathrm{IU}\right)\times \left(90\ \mathrm{days}\right)=307,800\ \mathrm{IU}\left(\mathrm{total}\ \mathrm{loading}\ \mathrm{dose}\right) $$\end{document}</tex-math><mml:math id="M2"><mml:mi mathvariant="normal">Loading</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">dose</mml:mi><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">daily</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">maintenance</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">dose</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.25em"/><mml:mn>3420</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">IU</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#x000d7;</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>90</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">days</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>307</mml:mn><mml:mo>,</mml:mo><mml:mn>800</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">IU</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">total</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">loading</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">dose</mml:mi></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="13063_2015_877_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p><p>In previous studies, researchers used doses exceeding this dosage, at 500,000 and 600,000&#x000a0;IU of cholecalciferol/vitamin D<sub>3</sub> in frail elderly patients, young patients, and critically ill patients, without observing any adverse effects (e.g., hypercalcemia) [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. The total loading dose of 300,000&#x000a0;IU is given on the basis of the measured 25-OHD blood levels and/or concentrations (except for the first dose, given at day 1 after surgery, of 100,000&#x000a0;IU) up to a maximum of 300,000&#x000a0;IU. To make the loading dose protocol safer, 100,000&#x000a0;IU of vitamin D is administered at one time to allow clearance from the circulation between each increment of the loading dose [<xref ref-type="bibr" rid="CR71">71</xref>].</p><p>According to the European Food Safety Authority (EFSA), the no observed adverse effect level was established at 10,000&#x000a0;IU per day and the tolerable upper intake level (UL) at 4000&#x000a0;IU per day (based on induction of hypercalcemia as the indicator of toxicity) [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. The maintenance dose, given after the loading dose, is 3420&#x000a0;IU per day, which is in accordance with the EFSA panel guideline of a UL of 4000&#x000a0;IU per day [<xref ref-type="bibr" rid="CR72">72</xref>]. Taken together, no harm or risk is expected for patients in the intervention and placebo groups. Importantly, as a result, appropriate selection of maintenance and loading doses can reduce the need for follow-up monitoring of 25-OHD levels.</p></sec><sec id="Sec13"><title>Intervention group</title><p>The oral loading dose of 300,000&#x000a0;IU cholecalciferol (vitamin D<sub>3</sub>) is divided into three doses (100,000&#x000a0;IU each) and is given on day 1 and at 2 and 4&#x000a0;weeks postoperatively. The oral maintenance dose is given up to 24&#x000a0;weeks and until the follow-up visit (46&#x000a0;weeks). All patients in the intervention group receive the first loading dose. The second and third doses are given based on the 25-OHD serum concentration, which is assessed before administration. If the 25-OHD does not reach a level above 75&#x000a0;nmol/L, a 100,000&#x000a0;IU dose is again given, up to 300,000&#x000a0;IU in total. After the last loading dose, a maintenance dose of 3420&#x000a0;IU per day (approximately translating to 60 drops and 24,000&#x000a0;IU per week) should maintain the high 25-OHD concentration, according to guidelines (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR23">23</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Dosing regimen. [25 - OHD 25-hydroxy vitamin D]</p></caption><graphic xlink:href="13063_2015_877_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec14"><title>Placebo group</title><p>The carrier solution (medium-chain triglyceride oil [MCT]), of the verum formulation (MCT&#x02009;+&#x02009;vitamin D) is used in the placebo-only group. The placebo group is treated exactly the same as the intervention group (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p></sec></sec><sec id="Sec15"><title>Measurements</title><p>Patient history and dietary assessment data are documented at baseline and collected four times. For all subjects, body weight, body composition, and blood parameters are assessed eight times. The liver function assessment is done four times. Blood pressure, depression symptoms, BMD, and total body fat mass are measured two times in all study groups. The visit and assessment schedule are shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><p>Flowchart. [BMD bone mineral density]</p></caption><graphic xlink:href="13063_2015_877_Fig3_HTML" id="MO3"/></fig></p><p>The measurements to be performed are described in the subsections below and in Table <xref rid="Tab2" ref-type="table">2</xref>.</p><sec id="Sec16"><title>History, blood pressure, and dietary assessment</title><p><list list-type="order"><list-item><p>Medical history, such as comorbidities, prescribed medications, and demographics (marital status, education, migration background, and career)</p></list-item><list-item><p>Blood pressure (mmHg)</p></list-item><list-item><p>Dietary assessment to provide information regarding dietary vitamin D intake as follows:<list list-type="alpha-lower"><list-item><p><italic>5</italic>-<italic>day food record</italic>: During the week before the scheduled visit, patients should record their food intake for 5&#x000a0;days. Data are analyzed using the nutritional software nut.s, which is based on Bundeslebensmittelschl&#x000fc;ssel (Max Rubner-Institut; <ext-link ext-link-type="uri" xlink:href="http://www.bls.nvs2.de/">http://www.bls.nvs2.de/</ext-link>).</p></list-item><list-item><p><italic>Mediterranean Adherence Score</italic>: A brief, validated questionnaire regarding adherence to the Mediterranean diet results on a 14-point scale [<xref ref-type="bibr" rid="CR74">74</xref>]; the higher the score, the better the adherence to the proposed diet</p></list-item></list></p></list-item></list></p></sec><sec id="Sec17"><title>Anthropometry</title><p><list list-type="order"><list-item><p>Weight (kg), measured with a calibrated scale</p></list-item><list-item><p>Height (cm), measured with a wall stadiometer</p></list-item><list-item><p>Waist circumference, measured with an inelastic tape</p></list-item><list-item><p><italic>Body composition</italic>: fat-free mass, lean body mass, total body water, and phase angle are assessed by bioelectrical impedance analysis (BIA) [<xref ref-type="bibr" rid="CR75">75</xref>], based on the transfer of a low-voltage alternating current through the body. This measurement captures the voltage drop of the applied current and result in measuring resistance and reactance. It is used with height, weight, age, and sex in a number of multiple regression relationships to calculate body composition compartments [<xref ref-type="bibr" rid="CR76">76</xref>]. A single frequency BIA at 50&#x000a0;kHz and 0.8&#x000a0;mA (Biacorpus RX 4000; MediCal HealthCare GmbH, Karlsruhe, Germany) is passed between electrodes (Bodystat, Isle of Man, UK) placed on the dominant side hand and foot with patients in the supine position.</p></list-item></list></p></sec><sec id="Sec18"><title>Stage of liver stiffness and steatosis</title><p>Transient elastography FibroScan (Echosens, Paris, France) with a controlled attenuation parameter (CAP&#x02122;) will be performed based on transmitting a vibration signal into the liver and receiving the resulting shear wave, which depends on liver stiffness. CAP&#x02122; measures ultrasonic attenuation in the liver at 3.5&#x000a0;MHz and detects liver steatosis.</p></sec><sec id="Sec19"><title>Bone mineral density and total body fat mass</title><p>Dual-energy X-ray absorptiometry (DEXA) will be used to measure bone mineral content, BMD, and percent body fat.</p></sec><sec id="Sec20"><title>Laboratory parameters</title><p><list list-type="order"><list-item><p><italic>Vitamin D status</italic>: 25-OHD (nmol/L), 1,25-dihydroxy vitamin D (pg/ml)</p></list-item><list-item><p><italic>Biochemical parameters</italic>: sodium (nmol/L), potassium (nmol/L), chloride (nmol/L), calcium (nmol/L), magnesium (nmol/L), iron (&#x003bc;g/dl), total protein (g/L), albumin (g/L), triglyceride (mg/dl), total cholesterol (mg/dl), high-density lipoprotein (mg/dl), low-density lipoprotein (mg/dl), vitamin B<sub>12</sub> (pmol/L), folic acid (nmol/L), vitamin A (&#x003bc;mol/L), vitamin E (&#x003bc;mol/L), ferritin (&#x003bc;g/L), transferrin (mg/dl), and transferrin saturation (%)</p></list-item><list-item><p><italic>Bone turnover markers</italic>: calcium (mmol/L), osteocalcin (ng/ml), bone-specific alkaline phosphatase (U/L), type I collagen cross-linked C-terminal telopeptide (ng/ml), anorganic phosphate (mmol/L), parathyroid hormone intact (pg/ml), and amino-terminal propeptide of type I procollagen (ng/ml)</p></list-item><list-item><p><italic>Inflammation markers</italic>: C-reactive protein (mg/dl) and interleukin 6 (pg/ml)</p></list-item><list-item><p><italic>Insulin resistance markers</italic>: C-peptide (ng/ml), insulin (&#x003bc;U/ml), blood glucose (mg/dl), and glycosylated hemoglobin HbA1c (%)</p></list-item><list-item><p><italic>Liver parameters</italic>: aspartate transaminase (U/L), alanine transaminase (U/L), &#x003b3;-glutamyl transpeptidase (U/L), total alkaline phosphatase (U/L), and cholinesterase (U/L)</p></list-item><list-item><p>Blood count</p></list-item><list-item><p><italic>Coagulation</italic>: Normotest (%) (Technoclone, Vienna, Austria), activated partial thromboplastin time (s), and fibrinogen (mg/dl)</p></list-item><list-item><p><italic>Protein electrophoresis</italic>: serum protein electrophoresis, haptoglobin (mg/dl), and &#x003b1;<sub>2</sub>-macroglobulin (mg/dl)</p></list-item></list></p></sec><sec id="Sec21"><title>Depression symptoms</title><p>The Beck Depression Inventory (BDI) [<xref ref-type="bibr" rid="CR77">77</xref>] (simplified BDI-V), a 21-question, multiple-choice, self-report inventory will be used for measuring the severity of depression [<xref ref-type="bibr" rid="CR78">78</xref>].</p></sec><sec id="Sec22"><title>Microbiota composition</title><p>Stool samples will be collected to evaluate changes in the composition of intestinal microbiota resulting from weight reduction and vitamin D supplementation.</p></sec><sec id="Sec23"><title>Biopsy</title><p>For the purposes of describing adipose depot vitamin D concentrations and expression of enzymes in SAT, visceral adipose VAT and liver tissue samples are collected by the surgeon during surgery. Furthermore, liver tissue samples are used, in addition to the prescribed study-related measures, for histological examination as extended diagnostics. Samples are snap-frozen in isopentane and stored in nitrogen tanks at &#x02212;196&#x000a0;&#x000b0;C until assayed. Biopsies will be performed as follows:<list list-type="order"><list-item><p><italic>Adipose tissue</italic>: The SAT sample is extracted through a linear incision in the abdominal wall with no additional incision. The VAT sample is taken from the greater omentum, coming off the transverse colon.</p></list-item><list-item><p><italic>Liver tissue</italic>: Standard intraoperative wedge and needle biopsies are collected during surgery.</p></list-item></list></p></sec></sec><sec id="Sec24"><title>Statistical analysis</title><p>Data exploration using descriptive statistical analysis and inferential statistics (uni- and multivariate) will be performed. The data will be described by frequencies or percentages, means and standard deviations, medians and confidence intervals, and graphics. For proofing of normal distributions, visual inspection of histograms or box plots will be used. Independent samples <italic>t</italic> tests, Mann&#x02013;Whitney <italic>U</italic> test or <italic>&#x003c7;</italic><sup>2</sup> tests will be performed to compare groups. Correlation coefficients will be used with respect to the secondary outcomes. Analysis of covariance will be used to compare parameters at baseline and after the intervention (postoperatively), as well as after the follow-up, between intervention and control groups, adjusting for the baseline value as a covariate. IBM SPSS Statistics for Windows version 22 software (IBM, Armonk, NY, USA) will be used for all statistical analyses. All tests are two-sided, and a <italic>p</italic> value &#x0003c;0.05 is considered statistically significant.</p></sec></sec><sec id="Sec25" sec-type="discussion"><title>Discussion</title><p>The major strengths of the proposed study are the prospective, randomized, double-blind, placebo-controlled design and the implementation of an independent evaluation of outcome parameters. The expected result, positive or negative, should provide an evidence-based and potentially optimal treatment of vitamin D deficiency following bariatric surgery and should define the interactions of vitamin D and specific factors, such as liver and bone health, inflammation, insulin resistance, blood pressure, depression symptoms, microbiota, and weight loss. Furthermore, as far as we know, the LOAD study is one of the first trials with this type of vitamin D supplementation in bariatric patients.</p><p>Some aspects of the study design, however, may deserve a closer discussion. Why was an active treatment regime after the loading dose chosen for the control group? From an ethical point of view, and bearing in mind the importance of vitamin D for bone metabolism, it would be difficult not to provide these patients with vitamin D supplementation at all. Therefore, we decided to use the placebo only for the loading dose (in the first postoperative month) to compare this dosing regimen with the usual supplementation. Indeed, with this study design, we expect to treat and provide supplements to the patients more effectively than in routine care.</p><p>The prospective benefit will have a positive impact on vitamin D status and therefore on the well-being and health-related quality of life, which has been described in the literature [<xref ref-type="bibr" rid="CR79">79</xref>&#x02013;<xref ref-type="bibr" rid="CR81">81</xref>]. A further question might be why a supplementation regimen different from an established treatment of vitamin D deficiency in bariatric patients was chosen. In fact, from a methodological point of view, a constant daily supplementation of vitamin D would be preferable. However, there is evidence in the literature that this standard supplementation in bariatric patients is not sufficient, and with this novel dosing regimen, the final vitamin D plateau could be achieved earlier than the four half-lives required when administered only at the maintenance dose rate [<xref ref-type="bibr" rid="CR65">65</xref>]. Another important point for the success of the LOAD study is the compliance of the participants regarding regular study visits. Hence, we are in close contact with the participants, and they are receiving text messages before the scheduled appointment.</p><p>Finally, one might assume that the rather small sample size of 50 bariatric patients in the proposed study might be underpowered to detect a significant difference between groups. However, the study is powered to detect differences between the groups for 24-week serum 25-OHD levels, with a given clinically relevant difference of 30&#x000a0;nmol/L and a standard deviation of 35&#x000a0;nmol/L of the differences. Thus, if high-dose supplementation with vitamin D is indeed effective, a reduction of vitamin D deficiency after 24&#x000a0;weeks would not be unrealistic.</p><p>In conclusion, this vitamin D supplementation regimen has the potential to be a safe, orally available, cheap, and evidence-based treatment of low vitamin D status following bariatric surgery in this increasingly prevalent group, and the study probably also is an opportunity to find an association between obesity and vitamin D deficiency.</p></sec><sec id="Sec26"><title>Trial status</title><p>The LOAD study commenced recruitment in April 2014. Recruitment was completed in April 2015.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BDI</term><def><p>Beck Depression Inventory</p></def></def-item><def-item><term>BIA</term><def><p>Bioelectrical impedance analysis</p></def></def-item><def-item><term>BMD</term><def><p>Bone mineral density</p></def></def-item><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>CAP</term><def><p>Controlled attenuation parameter</p></def></def-item><def-item><term>DEXA</term><def><p>Dual-energy X-ray absorptiometry</p></def></def-item><def-item><term>EFSA</term><def><p>European Food Safety Authority</p></def></def-item><def-item><term>GFR</term><def><p>Glomerular filtration rate</p></def></def-item><def-item><term>LOAD</term><def><p>Link between Obesity And Vitamin D in bariatric patients with omega-loop bypass surgery</p></def></def-item><def-item><term>MCT</term><def><p>Medium-chain triglyceride</p></def></def-item><def-item><term>NAFLD</term><def><p>Non-alcoholic fatty liver disease</p></def></def-item><def-item><term>25-OHD</term><def><p>25-hydroxy vitamin D</p></def></def-item><def-item><term>OLGB</term><def><p>Omega-loop gastric bypass</p></def></def-item><def-item><term>RYGB</term><def><p>Roux-en-Y gastric bypass</p></def></def-item><def-item><term>SAT</term><def><p>Subcutaneous adipose tissue</p></def></def-item><def-item><term>UL</term><def><p>Tolerable upper intake level</p></def></def-item><def-item><term>VAT</term><def><p>Visceral adipose tissue</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>ML, RK, RM, EK, BL, CHK, ST, and MT designed the trial. ML, RK, FL, CHK, ST, CK, MEK, TW, HH, MT, FH, RM, KS, GP, and BL are responsible for the conduct of the trial. ML, EL, RK, and CK drafted the manuscript. All authors read and approved the final manuscript.</p></fn><fn><p><bold>Authors&#x02019; information</bold></p><p>ML: nutritionist, doctoral student, research associate at the Department of Internal Medicine III, Medical University of Vienna and at the Special Institute for Preventive Cardiology and Nutrition</p><p>RK: medical doctor at the Department of Internal Medicine III, Medical University of Vienna</p><p>RM: medical doctor, associate professor at the Department of Laboratory Medicine, Medical University of Vienna</p><p>FL: medical doctor, associate professor at the Department of Surgery, Medical University of Vienna</p><p>CHK: medical doctor at the Department of Internal Medicine III, Medical University of Vienna</p><p>ST: medical doctor at the Department of Internal Medicine III, Medical University of Vienna</p><p>CK: nutritionist and graduate student at the Department of Internal Medicine III, Medical University of Vienna</p><p>MEK: dietician at the Department of Internal Medicine III, Medical University of Vienna</p><p>KS: nutritionist, associate professor at the Department of Internal Medicine III, Medical University of Vienna</p><p>EL: nutritionist and doctoral student at the Institute of Social Medicine, Center for Public Health, Medical University of Vienna</p><p>TW: medical doctor at the Department of Pathology, Medical University of Vienna</p><p>HH: research associate at the Department of Laboratory Medicine, Medical University of Vienna</p><p>MT: medical doctor, professor and chair of gastroenterology/hepatology at the Department of Internal Medicine III, Medical University of Vienna</p><p>FH: medical doctor, associate professor at the Special Institute for Preventive Cardiology and Nutrition</p><p>EK: biochemist, associate professor at the Department of Pathophysiology and Allergy Research, Medical University of Vienna</p><p>GP: medical doctor, associate professor at the Department of Surgery, Medical University of Vienna</p><p>BL: medical doctor, associate professor at the Department of Internal Medicine III, Medical University of Vienna</p></fn></fn-group><ack><p>This study will be conducted in cooperation with the MedUni Wien Biobank. We are grateful to Fresenius Kabi and Aengus for supplying, cost-free, the Oleovit and placebo oil and the BIA for this study population. This research receives no specific grant from any funding agency or from the commercial or not-for-profit sector.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popkin</surname><given-names>BM</given-names></name></person-group><article-title>Recent dynamics suggest selected countries catching up to US obesity</article-title><source>Am J Clin Nutr</source><year>2010</year><volume>91</volume><issue>1</issue><fpage>284S</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2009.28473C</pub-id><pub-id pub-id-type="pmid">19906804</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botella-Carretero</surname><given-names>JI</given-names></name><name><surname>Alvarez-Blasco</surname><given-names>F</given-names></name><name><surname>Villafruela</surname><given-names>JJ</given-names></name><name><surname>Balsa</surname><given-names>JA</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>C</given-names></name><name><surname>Escobar-Morreale</surname><given-names>HF</given-names></name></person-group><article-title>Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity</article-title><source>Clin Nutr</source><year>2007</year><volume>26</volume><issue>5</issue><fpage>573</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2007.05.009</pub-id><pub-id pub-id-type="pmid">17624643</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayaniyil</surname><given-names>S</given-names></name><name><surname>Vieth</surname><given-names>R</given-names></name><name><surname>Harris</surname><given-names>SB</given-names></name><name><surname>Retnakaran</surname><given-names>R</given-names></name><name><surname>Knight</surname><given-names>JA</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><issue>1</issue><fpage>168</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-1439</pub-id><pub-id pub-id-type="pmid">20980431</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Beydoun</surname><given-names>MA</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Caballero</surname><given-names>B</given-names></name><name><surname>Kumanyika</surname><given-names>SK</given-names></name></person-group><article-title>Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic</article-title><source>Obesity (Silver Spring)</source><year>2008</year><volume>16</volume><issue>10</issue><fpage>2323</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/oby.2008.351</pub-id><pub-id pub-id-type="pmid">18719634</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yach</surname><given-names>D</given-names></name><name><surname>Stuckler</surname><given-names>D</given-names></name><name><surname>Brownell</surname><given-names>KD</given-names></name></person-group><article-title>Epidemiologic and economic consequences of the global epidemics of obesity and diabetes</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><issue>1</issue><fpage>62</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nm0106-62</pub-id><pub-id pub-id-type="pmid">16397571</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchwald</surname><given-names>H</given-names></name><name><surname>Oien</surname><given-names>DM</given-names></name></person-group><article-title>Metabolic/bariatric surgery worldwide 2008</article-title><source>Obes Surg</source><year>2009</year><volume>19</volume><issue>12</issue><fpage>1605</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/s11695-009-0014-5</pub-id><pub-id pub-id-type="pmid">19885707</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjostrom</surname><given-names>L</given-names></name><name><surname>Narbro</surname><given-names>K</given-names></name><name><surname>Sj&#x000f6;str&#x000f6;m</surname><given-names>CD</given-names></name><name><surname>Karason</surname><given-names>K</given-names></name><name><surname>Larsson</surname><given-names>B</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effects of bariatric surgery on mortality in Swedish obese subjects</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><issue>8</issue><fpage>741</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa066254</pub-id><pub-id pub-id-type="pmid">17715408</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gloth</surname><given-names>FM</given-names></name><name><surname>Alam</surname><given-names>W</given-names></name><name><surname>Hollis</surname><given-names>B</given-names></name></person-group><article-title>Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder</article-title><source>J Nutr Health Aging</source><year>1999</year><volume>3</volume><issue>1</issue><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10888476</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechanick</surname><given-names>JI</given-names></name><name><surname>Kushner</surname><given-names>RF</given-names></name><name><surname>Sugerman</surname><given-names>HJ</given-names></name><name><surname>Gonzalez-Campoy</surname><given-names>JM</given-names></name><name><surname>Collazo-Clavell</surname><given-names>ML</given-names></name><name><surname>Spitz</surname><given-names>AF</given-names></name><etal/></person-group><article-title>American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic &#x00026; Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient</article-title><source>Obesity (Silver Spring)</source><year>2008</year><volume>17 Suppl 1</volume><fpage>1</fpage><lpage>70</lpage></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnon</surname><given-names>LE</given-names></name><name><surname>Karwacki Sheff</surname><given-names>EJ</given-names></name></person-group><article-title>Outcomes and complications after bariatric surgery</article-title><source>Am J Nurs</source><year>2012</year><volume>112</volume><issue>9</issue><fpage>26</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1097/01.NAJ.0000418920.45600.7a</pub-id><pub-id pub-id-type="pmid">22902899</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aasheim</surname><given-names>ET</given-names></name><name><surname>Bjorkman</surname><given-names>S</given-names></name><name><surname>Sovik</surname><given-names>TT</given-names></name><name><surname>Engstrom</surname><given-names>M</given-names></name><name><surname>Hanvold</surname><given-names>SE</given-names></name><name><surname>Mala</surname><given-names>T</given-names></name><etal/></person-group><article-title>Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch</article-title><source>Am J Clin Nutr</source><year>2009</year><volume>90</volume><issue>1</issue><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2009.27583</pub-id><pub-id pub-id-type="pmid">19439456</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aasheim</surname><given-names>ET</given-names></name><name><surname>Hofso</surname><given-names>D</given-names></name><name><surname>Hjelmesaeth</surname><given-names>J</given-names></name><name><surname>Birkeland</surname><given-names>KI</given-names></name><name><surname>Bohmer</surname><given-names>T</given-names></name></person-group><article-title>Vitamin status in morbidly obese patients: a cross-sectional study</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>87</volume><issue>2</issue><fpage>362</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18258626</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasteyger</surname><given-names>C</given-names></name><name><surname>Suter</surname><given-names>M</given-names></name><name><surname>Gaillard</surname><given-names>RC</given-names></name><name><surname>Giusti</surname><given-names>V</given-names></name></person-group><article-title>Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standard multivitamin supplementation</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>87</volume><issue>5</issue><fpage>1128</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">18469230</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledoux</surname><given-names>S</given-names></name><name><surname>Larger</surname><given-names>E</given-names></name></person-group><article-title>Nutritional deficiencies after Roux-en-Y gastric bypass can be prevented by standard multivitamin supplementation</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>88</volume><issue>4</issue><fpage>1176</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18842809</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skroubis</surname><given-names>G</given-names></name><name><surname>Sakellaropoulos</surname><given-names>G</given-names></name><name><surname>Pouggouras</surname><given-names>K</given-names></name><name><surname>Mead</surname><given-names>N</given-names></name><name><surname>Nikiforidis</surname><given-names>G</given-names></name><name><surname>Kalfarentzos</surname><given-names>F</given-names></name></person-group><article-title>Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass</article-title><source>Obes Surg</source><year>2002</year><volume>12</volume><issue>4</issue><fpage>551</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1381/096089202762252334</pub-id><pub-id pub-id-type="pmid">12194550</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sovik</surname><given-names>TT</given-names></name><name><surname>Aasheim</surname><given-names>ET</given-names></name><name><surname>Taha</surname><given-names>O</given-names></name><name><surname>Engstrom</surname><given-names>M</given-names></name><name><surname>Fagerland</surname><given-names>MW</given-names></name><name><surname>Bjorkman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Weight loss, cardiovascular risk factors, and quality of life after gastric bypass and duodenal switch: a randomized trial</article-title><source>Ann Intern Med</source><year>2011</year><volume>155</volume><issue>5</issue><fpage>281</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-155-5-201109060-00005</pub-id><pub-id pub-id-type="pmid">21893621</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname><given-names>ON</given-names></name><name><surname>Szomstein</surname><given-names>S</given-names></name><name><surname>Rosenthal</surname><given-names>RJ</given-names></name></person-group><article-title>Nutritional consequences of weight-loss surgery</article-title><source>Med Clin North Am</source><year>2007</year><volume>91</volume><issue>3</issue><fpage>499</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/j.mcna.2007.01.006</pub-id><pub-id pub-id-type="pmid">17509392</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>O</given-names></name><name><surname>Sirveaux</surname><given-names>MA</given-names></name><name><surname>Brunaud</surname><given-names>L</given-names></name><name><surname>Reibel</surname><given-names>N</given-names></name><name><surname>Quilliot</surname><given-names>D</given-names></name></person-group><article-title>Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies</article-title><source>Diabetes Metab</source><year>2009</year><volume>35</volume><issue>6 Pt 2</issue><fpage>544</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/S1262-3636(09)73464-0</pub-id><pub-id pub-id-type="pmid">20152742</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>V</given-names></name><name><surname>Silecchia</surname><given-names>G</given-names></name></person-group><article-title>Vitamin D status and supplementation in morbid obesity before and after bariatric surgery</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2010</year><volume>4</volume><issue>6</issue><fpage>781</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1586/egh.10.69</pub-id><pub-id pub-id-type="pmid">21108597</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Censani</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>EM</given-names></name><name><surname>Shane</surname><given-names>E</given-names></name><name><surname>Oberfield</surname><given-names>SE</given-names></name><name><surname>McMahon</surname><given-names>DJ</given-names></name><name><surname>Lerner</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vitamin D deficiency is prevalent in morbidly obese adolescents prior to bariatric surgery</article-title><source>ISRN Obes</source><year>2013</year><volume>2013</volume><fpage>284516</fpage><pub-id pub-id-type="pmid">23724340</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducloux</surname><given-names>R</given-names></name><name><surname>Nobecourt</surname><given-names>E</given-names></name><name><surname>Chevallier</surname><given-names>JM</given-names></name><name><surname>Ducloux</surname><given-names>H</given-names></name><name><surname>Elian</surname><given-names>N</given-names></name><name><surname>Altman</surname><given-names>JJ</given-names></name></person-group><article-title>Vitamin D deficiency before bariatric surgery: should supplement intake be routinely prescribed?</article-title><source>Obes Surg</source><year>2011</year><volume>21</volume><issue>5</issue><fpage>556</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1007/s11695-010-0352-3</pub-id><pub-id pub-id-type="pmid">21234699</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fish</surname><given-names>E</given-names></name><name><surname>Beverstein</surname><given-names>G</given-names></name><name><surname>Olson</surname><given-names>D</given-names></name><name><surname>Reinhardt</surname><given-names>S</given-names></name><name><surname>Garren</surname><given-names>M</given-names></name><name><surname>Gould</surname><given-names>J</given-names></name></person-group><article-title>Vitamin D status of morbidly obese bariatric surgery patients</article-title><source>J Surg Res</source><year>2010</year><volume>164</volume><issue>2</issue><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2010.06.029</pub-id><pub-id pub-id-type="pmid">20850786</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechanick</surname><given-names>JI</given-names></name><name><surname>Youdim</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>DB</given-names></name><name><surname>Garvey</surname><given-names>WT</given-names></name><name><surname>Hurley</surname><given-names>DL</given-names></name><name><surname>McMahon</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient&#x02014;2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic &#x00026; Bariatric Surgery</article-title><source>Endocr Pract</source><year>2013</year><volume>19</volume><issue>2</issue><fpage>337</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.4158/EP12437.GL</pub-id><pub-id pub-id-type="pmid">23529351</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artaza</surname><given-names>JN</given-names></name><name><surname>Mehrotra</surname><given-names>R</given-names></name><name><surname>Norris</surname><given-names>KC</given-names></name></person-group><article-title>Vitamin D and the cardiovascular system</article-title><source>Clin J Am Soc Nephrol</source><year>2009</year><volume>4</volume><issue>9</issue><fpage>1515</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.2215/CJN.02260409</pub-id><pub-id pub-id-type="pmid">19696220</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osei</surname><given-names>K</given-names></name></person-group><article-title>25-OH vitamin D: is it the universal panacea for metabolic syndrome and type 2 diabetes?</article-title><source>J Clin Endocrinol Metab</source><year>2010</year><volume>95</volume><issue>9</issue><fpage>4220</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-1550</pub-id><pub-id pub-id-type="pmid">20823471</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozfirat</surname><given-names>Z</given-names></name><name><surname>Chowdhury</surname><given-names>TA</given-names></name></person-group><article-title>Vitamin D deficiency and type 2 diabetes</article-title><source>Postgrad Med J</source><year>2010</year><volume>86</volume><issue>1011</issue><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1136/pgmj.2009.078626</pub-id><pub-id pub-id-type="pmid">20065337</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anglin</surname><given-names>RE</given-names></name><name><surname>Samaan</surname><given-names>Z</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name><name><surname>McDonald</surname><given-names>SD</given-names></name></person-group><article-title>Vitamin D deficiency and depression in adults: systematic review and meta-analysis</article-title><source>Br J Psychiatry</source><year>2013</year><volume>202</volume><fpage>100</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.111.106666</pub-id><pub-id pub-id-type="pmid">23377209</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorde</surname><given-names>R</given-names></name><name><surname>Sneve</surname><given-names>M</given-names></name><name><surname>Figenschau</surname><given-names>Y</given-names></name><name><surname>Svartberg</surname><given-names>J</given-names></name><name><surname>Waterloo</surname><given-names>K</given-names></name></person-group><article-title>Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial</article-title><source>J Intern Med</source><year>2008</year><volume>264</volume><issue>6</issue><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2008.02008.x</pub-id><pub-id pub-id-type="pmid">18793245</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjaergaard</surname><given-names>M</given-names></name><name><surname>Waterloo</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>CE</given-names></name><name><surname>Almas</surname><given-names>B</given-names></name><name><surname>Figenschau</surname><given-names>Y</given-names></name><name><surname>Hutchinson</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case&#x02013;control study and randomised clinical trial</article-title><source>Br J Psychiatry</source><year>2012</year><volume>201</volume><issue>5</issue><fpage>360</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.111.104349</pub-id><pub-id pub-id-type="pmid">22790678</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foss</surname><given-names>YJ</given-names></name></person-group><article-title>Vitamin D, deficiency is the cause of common obesity</article-title><source>Med Hypotheses</source><year>2009</year><volume>72</volume><issue>3</issue><fpage>314</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2008.10.005</pub-id><pub-id pub-id-type="pmid">19054627</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellia</surname><given-names>A</given-names></name><name><surname>Garcovich</surname><given-names>C</given-names></name><name><surname>D&#x02019;Adamo</surname><given-names>M</given-names></name><name><surname>Lombardo</surname><given-names>M</given-names></name><name><surname>Tesauro</surname><given-names>M</given-names></name><name><surname>Donadel</surname><given-names>G</given-names></name><etal/></person-group><article-title>Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects</article-title><source>Intern Emerg Med</source><year>2013</year><volume>8</volume><issue>1</issue><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1007/s11739-011-0559-x</pub-id><pub-id pub-id-type="pmid">21437585</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Tavera-Mendoza</surname><given-names>LE</given-names></name><name><surname>Laperriere</surname><given-names>D</given-names></name><name><surname>Libby</surname><given-names>E</given-names></name><name><surname>MacLeod</surname><given-names>NB</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Large-scale <italic>in silico</italic> and microarray-based identification of direct 1,25-dihydroxyvitamin D<sub>3</sub> target genes</article-title><source>Mol Endocrinol</source><year>2005</year><volume>19</volume><issue>11</issue><fpage>2685</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1210/me.2005-0106</pub-id><pub-id pub-id-type="pmid">16002434</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ching</surname><given-names>S</given-names></name><name><surname>Kashinkunti</surname><given-names>S</given-names></name><name><surname>Niehaus</surname><given-names>MD</given-names></name><name><surname>Zinser</surname><given-names>GM</given-names></name></person-group><article-title>Mammary adipocytes bioactivate 25-hydroxyvitamin D<sub>3</sub> and signal via vitamin D<sub>3</sub> receptor, modulating mammary epithelial cell growth</article-title><source>J Cell Biochem</source><year>2011</year><volume>112</volume><issue>11</issue><fpage>3393</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1002/jcb.23273</pub-id><pub-id pub-id-type="pmid">21769914</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>KE</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Szeto</surname><given-names>FL</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Deb</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><issue>39</issue><fpage>33804</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.257568</pub-id><pub-id pub-id-type="pmid">21840998</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Byrne</surname><given-names>ME</given-names></name><name><surname>Chang</surname><given-names>E</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Donkin</surname><given-names>SS</given-names></name><name><surname>Buhman</surname><given-names>KK</given-names></name><etal/></person-group><article-title>1&#x003b1;,25-Dihydroxyvitamin D hydroxylase in adipocytes</article-title><source>J Steroid Biochem Mol Biol</source><year>2008</year><volume>112</volume><issue>1&#x02013;3</issue><fpage>122</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2008.09.006</pub-id><pub-id pub-id-type="pmid">18840526</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Molecular mechanism of 1,25-dihydroxyvitamin D<sub>3</sub> inhibition of adipogenesis in 3T3-L1 cells</article-title><source>Am J Physiol Endocrinol Metab</source><year>2003</year><volume>290</volume><fpage>E916</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00410.2005</pub-id><pub-id pub-id-type="pmid">16368784</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamei</surname><given-names>Y</given-names></name><name><surname>Kawada</surname><given-names>T</given-names></name><name><surname>Kazuki</surname><given-names>R</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Sugimoto</surname><given-names>E</given-names></name></person-group><article-title>Vitamin D receptor gene expression is up-regulated by 1,25-dihydroxyvitamin D<sub>3</sub> in 3T3-L1 preadipocytes</article-title><source>Biochem Biophys Res Commun</source><year>1993</year><volume>193</volume><issue>3</issue><fpage>948</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1993.1717</pub-id><pub-id pub-id-type="pmid">7686756</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalasani</surname><given-names>N</given-names></name><name><surname>Younossi</surname><given-names>Z</given-names></name><name><surname>Lavine</surname><given-names>JE</given-names></name><name><surname>Diehl</surname><given-names>AM</given-names></name><name><surname>Brunt</surname><given-names>EM</given-names></name><name><surname>Cusi</surname><given-names>K</given-names></name><etal/></person-group><article-title>The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology</article-title><source>Gastroenterology</source><year>2012</year><volume>142</volume><issue>7</issue><fpage>1592</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2012.04.001</pub-id><pub-id pub-id-type="pmid">22656328</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazo</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name></person-group><article-title>The epidemiology of nonalcoholic fatty liver disease: a global perspective</article-title><source>Semin Liver Dis</source><year>2008</year><volume>28</volume><fpage>339</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1091978</pub-id><pub-id pub-id-type="pmid">18956290</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blachier</surname><given-names>M</given-names></name><name><surname>Leleu</surname><given-names>H</given-names></name><name><surname>Peck-Radosavljevic</surname><given-names>M</given-names></name><name><surname>Valla</surname><given-names>DC</given-names></name><name><surname>Roudot-Thoraval</surname><given-names>F</given-names></name></person-group><article-title>The burden of liver disease in Europe: a review of available epidemiological data</article-title><source>J Hepatol</source><year>2013</year><volume>58</volume><issue>3</issue><fpage>593</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.12.005</pub-id><pub-id pub-id-type="pmid">23419824</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charlton</surname><given-names>MR</given-names></name><name><surname>Burns</surname><given-names>JM</given-names></name><name><surname>Pedersen</surname><given-names>RA</given-names></name><name><surname>Watt</surname><given-names>KD</given-names></name><name><surname>Heimbach</surname><given-names>JK</given-names></name><name><surname>Dierkhising</surname><given-names>RA</given-names></name></person-group><article-title>Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States</article-title><source>Gastroenterology</source><year>2011</year><volume>141</volume><issue>4</issue><fpage>1249</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.06.061</pub-id><pub-id pub-id-type="pmid">21726509</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Naalt</surname><given-names>SJ</given-names></name><name><surname>Gurria</surname><given-names>JP</given-names></name><name><surname>Holterman</surname><given-names>AL</given-names></name></person-group><article-title>Surgical treatment of nonalcoholic fatty liver disease in severely obese patients</article-title><source>Hepat Med</source><year>2014</year><volume>6</volume><fpage>103</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">25378958</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eliades</surname><given-names>M</given-names></name><name><surname>Spyrou</surname><given-names>E</given-names></name><name><surname>Agrawal</surname><given-names>N</given-names></name><name><surname>Lazo</surname><given-names>M</given-names></name><name><surname>Brancati</surname><given-names>FL</given-names></name><name><surname>Potter</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Meta-analysis: vitamin D and non-alcoholic fatty liver disease</article-title><source>Aliment Pharmacol Ther</source><year>2013</year><volume>38</volume><fpage>246</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1111/apt.12377</pub-id><pub-id pub-id-type="pmid">23786213</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>T</given-names></name><name><surname>Antony</surname><given-names>S</given-names></name><name><surname>Jayanarayanan</surname><given-names>S</given-names></name><name><surname>Paulose</surname><given-names>C</given-names></name></person-group><article-title>Effect of vitamin D<sub>3</sub> in reducing metabolic and oxidative stress in the liver of streptozotocin-induced diabetic rats</article-title><source>Br J Nutr</source><year>2012</year><volume>108</volume><fpage>1410</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1017/S0007114511006830</pub-id><pub-id pub-id-type="pmid">22221397</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>C</given-names></name><name><surname>Elfers</surname><given-names>C</given-names></name><name><surname>Figlewicz</surname><given-names>D</given-names></name><name><surname>Melhorn</surname><given-names>S</given-names></name><name><surname>Morton</surname><given-names>G</given-names></name><name><surname>Hoofnagle</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation</article-title><source>Hepatology</source><year>2012</year><volume>55</volume><issue>5</issue><fpage>1103</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1002/hep.24737</pub-id><pub-id pub-id-type="pmid">21994008</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name></person-group><article-title>Calcitriol inhibits hepatocyte apoptosis in rat allograft by regulating apoptosis-associated genes</article-title><source>Int Immunopharmacol</source><year>2007</year><volume>7</volume><fpage>1122</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2007.03.007</pub-id><pub-id pub-id-type="pmid">17570329</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potter</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Koteish</surname><given-names>A</given-names></name><name><surname>Mezey</surname><given-names>E</given-names></name></person-group><article-title>1,25-dihydroxyvitamin D<sub>3</sub> and its nuclear receptor repress human &#x003b1;<sub>1</sub>(I) collagen expression and type I collagen formation</article-title><source>Liver Int</source><year>2013</year><volume>33</volume><fpage>677</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1111/liv.12122</pub-id><pub-id pub-id-type="pmid">23413886</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csendes</surname><given-names>A</given-names></name><name><surname>Smok</surname><given-names>G</given-names></name><name><surname>Burgos</surname><given-names>AM</given-names></name></person-group><article-title>Histological findings in the liver before and after gastric bypass</article-title><source>Obes Surg</source><year>2006</year><volume>16</volume><issue>5</issue><fpage>607</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1381/096089206776944904</pub-id><pub-id pub-id-type="pmid">16687030</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>M</given-names></name><name><surname>Marques-Vidal</surname><given-names>P</given-names></name><name><surname>Cortez-Pinto</surname><given-names>H</given-names></name></person-group><article-title>Hepatic histology in obese patients undergoing bariatric surgery</article-title><source>J Hepatol</source><year>2006</year><volume>45</volume><issue>4</issue><fpage>600</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2006.06.013</pub-id><pub-id pub-id-type="pmid">16899321</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Leone</surname><given-names>N</given-names></name><name><surname>Vanni</surname><given-names>E</given-names></name><name><surname>Marchesini</surname><given-names>G</given-names></name><name><surname>Brunello</surname><given-names>F</given-names></name><name><surname>Carucci</surname><given-names>P</given-names></name><etal/></person-group><article-title>Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma</article-title><source>Gastroenterology</source><year>2002</year><volume>123</volume><issue>1</issue><fpage>134</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1053/gast.2002.34168</pub-id><pub-id pub-id-type="pmid">12105842</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matteoni</surname><given-names>CA</given-names></name><name><surname>Younossi</surname><given-names>ZM</given-names></name><name><surname>Gramlich</surname><given-names>T</given-names></name><name><surname>Boparai</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name><name><surname>McCullough</surname><given-names>AJ</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity</article-title><source>Gastroenterology</source><year>1999</year><volume>116</volume><issue>6</issue><fpage>1413</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(99)70506-8</pub-id><pub-id pub-id-type="pmid">10348825</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>A</given-names></name><name><surname>Nitta</surname><given-names>H</given-names></name><name><surname>Otsuka</surname><given-names>K</given-names></name><name><surname>Umemura</surname><given-names>A</given-names></name><name><surname>Baba</surname><given-names>S</given-names></name><name><surname>Obuchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments</article-title><source>Front Endocrinol</source><year>2014</year><volume>5</volume><fpage>164</fpage><pub-id pub-id-type="doi">10.3389/fendo.2014.00164</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldner</surname><given-names>WS</given-names></name><name><surname>Stoner</surname><given-names>JA</given-names></name><name><surname>Lyden</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>Larson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial</article-title><source>Obes Surg</source><year>2009</year><volume>19</volume><issue>2</issue><fpage>173</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s11695-008-9680-y</pub-id><pub-id pub-id-type="pmid">18795378</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luger</surname><given-names>M</given-names></name><name><surname>Kruschitz</surname><given-names>R</given-names></name><name><surname>Langer</surname><given-names>F</given-names></name><name><surname>Prager</surname><given-names>G</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Marculescu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effects of omega-loop gastric bypass on vitamin D and bone metabolism in morbidly obese bariatric patients</article-title><source>Obes Surg</source><year>2015</year><volume>25</volume><issue>6</issue><fpage>1056</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s11695-014-1492-7</pub-id><pub-id pub-id-type="pmid">25381120</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>NH</given-names></name><name><surname>Epstein</surname><given-names>S</given-names></name><name><surname>Greene</surname><given-names>A</given-names></name><name><surname>Shary</surname><given-names>J</given-names></name><name><surname>Oexmann</surname><given-names>MJ</given-names></name><name><surname>Shaw</surname><given-names>S</given-names></name></person-group><article-title>Evidence for alteration of the vitamin D-endocrine system in obese subjects</article-title><source>J Clin Invest</source><year>1985</year><volume>76</volume><issue>1</issue><fpage>370</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1172/JCI111971</pub-id><pub-id pub-id-type="pmid">2991340</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wortsman</surname><given-names>J</given-names></name><name><surname>Matsuoka</surname><given-names>LY</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><article-title>Decreased bioavailability of vitamin D in obesity</article-title><source>Am J Clin Nutr</source><year>2000</year><volume>72</volume><issue>3</issue><fpage>690</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10966885</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>O</given-names></name><name><surname>Salo</surname><given-names>M</given-names></name></person-group><article-title>The Helsinki Declaration, research guidelines and regulations: present and future editorial aspects</article-title><source>Acta Anaesthesiol Scand</source><year>1996</year><volume>40</volume><issue>7</issue><fpage>771</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.1996.tb04530.x</pub-id><pub-id pub-id-type="pmid">8874560</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><collab>CONSORT Group</collab></person-group><article-title>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</article-title><source>Trials</source><year>2010</year><volume>11</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-11-32</pub-id><pub-id pub-id-type="pmid">20334632</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clements</surname><given-names>RH</given-names></name><name><surname>Yellumahanthi</surname><given-names>K</given-names></name><name><surname>Wesley</surname><given-names>M</given-names></name><name><surname>Ballem</surname><given-names>N</given-names></name><name><surname>Bland</surname><given-names>KI</given-names></name></person-group><article-title>Hyperparathyroidism and vitamin D deficiency after laparoscopic gastric bypass</article-title><source>Am Surg</source><year>2008</year><volume>74</volume><issue>6</issue><fpage>469</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">18556987</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Maher</surname><given-names>JW</given-names></name><name><surname>DeMaria</surname><given-names>EJ</given-names></name><name><surname>Downs</surname><given-names>RW</given-names></name><name><surname>Wolfe</surname><given-names>LG</given-names></name><name><surname>Kellum</surname><given-names>JM</given-names></name></person-group><article-title>The long-term effects of gastric bypass on vitamin D metabolism</article-title><source>Ann Surg</source><year>2006</year><volume>243</volume><issue>5</issue><fpage>701</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000216773.47825.c1</pub-id><pub-id pub-id-type="pmid">16633006</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Signori</surname><given-names>C</given-names></name><name><surname>Zalesin</surname><given-names>KC</given-names></name><name><surname>Franklin</surname><given-names>B</given-names></name><name><surname>Miller</surname><given-names>WL</given-names></name><name><surname>McCullough</surname><given-names>PA</given-names></name></person-group><article-title>Effect of gastric bypass on vitamin D and secondary hyperparathyroidism</article-title><source>Obes Surg</source><year>2010</year><volume>20</volume><issue>7</issue><fpage>949</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s11695-010-0178-z</pub-id><pub-id pub-id-type="pmid">20443152</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wree</surname><given-names>A</given-names></name><name><surname>Schlattjan</surname><given-names>M</given-names></name><name><surname>Bechmann</surname><given-names>LP</given-names></name><name><surname>Claudel</surname><given-names>T</given-names></name><name><surname>Sowa</surname><given-names>JP</given-names></name><name><surname>Stojakovic</surname><given-names>T</given-names></name><etal/></person-group><article-title>Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients</article-title><source>Metabolism</source><year>2014</year><volume>63</volume><issue>12</issue><fpage>1542</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2014.09.001</pub-id><pub-id pub-id-type="pmid">25267016</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starmann</surname><given-names>J</given-names></name><name><surname>Falth</surname><given-names>M</given-names></name><name><surname>Spindelbock</surname><given-names>W</given-names></name><name><surname>Lanz</surname><given-names>KL</given-names></name><name><surname>Lackner</surname><given-names>C</given-names></name><name><surname>Zatloukal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>10</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0046584</pub-id><pub-id pub-id-type="pmid">23071592</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Medical Statistics and Informatics, Medical University of Vienna. Randomizer for clinical trials. <ext-link ext-link-type="uri" xlink:href="https://www.randomizer.at/">https://www.randomizer.at/</ext-link>. Accessed 14 April 2014.</mixed-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kenakin</surname><given-names>TP</given-names></name></person-group><article-title>Pharmacokinetics</article-title><source>A pharmacology primer: theory, applications, and methods</source><year>2009</year><publisher-loc>Oxford, UK</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>179</fpage><lpage>214</lpage></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacon</surname><given-names>CJ</given-names></name><name><surname>Gamble</surname><given-names>GD</given-names></name><name><surname>Horne</surname><given-names>AM</given-names></name><name><surname>Scott</surname><given-names>MA</given-names></name><name><surname>Reid</surname><given-names>IR</given-names></name></person-group><article-title>High-dose oral vitamin D<sub>3</sub> supplementation in the elderly</article-title><source>Osteoporos Int</source><year>2009</year><volume>20</volume><issue>8</issue><fpage>1407</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s00198-008-0814-9</pub-id><pub-id pub-id-type="pmid">19101755</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mawer</surname><given-names>EB</given-names></name><name><surname>Backhouse</surname><given-names>J</given-names></name><name><surname>Holman</surname><given-names>CA</given-names></name><name><surname>Lumb</surname><given-names>GA</given-names></name><name><surname>Stanbury</surname><given-names>SW</given-names></name></person-group><article-title>The distribution and storage of vitamin D and its metabolites in human tissues</article-title><source>Clin Sci</source><year>1972</year><volume>43</volume><issue>3</issue><fpage>413</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">4342673</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieth</surname><given-names>R</given-names></name></person-group><article-title>Vitamin D, supplementation, 25-hydroxyvitamin D concentrations, and safety</article-title><source>Am J Clin Nutr</source><year>1999</year><volume>69</volume><issue>5</issue><fpage>842</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">10232622</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipriani</surname><given-names>C</given-names></name><name><surname>Romagnoli</surname><given-names>E</given-names></name><name><surname>Scillitani</surname><given-names>A</given-names></name><name><surname>Chiodini</surname><given-names>I</given-names></name><name><surname>Clerico</surname><given-names>R</given-names></name><name><surname>Carnevale</surname><given-names>V</given-names></name><etal/></person-group><article-title>Effect of a single oral dose of 600,000 IU of cholecalciferol on serum calciotropic hormones in young subjects with vitamin D deficiency: a prospective intervention study</article-title><source>J Clin Endocrinol Metab</source><year>2010</year><volume>95</volume><issue>10</issue><fpage>4771</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-0502</pub-id><pub-id pub-id-type="pmid">20660032</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amrein</surname><given-names>K</given-names></name><name><surname>Schnedl</surname><given-names>C</given-names></name><name><surname>Holl</surname><given-names>A</given-names></name><name><surname>Riedl</surname><given-names>R</given-names></name><name><surname>Christopher</surname><given-names>KB</given-names></name><name><surname>Pachler</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of high-dose vitamin D<sub>3</sub> on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial</article-title><source>JAMA</source><year>2014</year><volume>312</volume><issue>15</issue><fpage>1520</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.13204</pub-id><pub-id pub-id-type="pmid">25268295</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vieth</surname><given-names>R</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Feldman</surname><given-names>D</given-names></name><name><surname>Pike</surname><given-names>JW</given-names></name><name><surname>Adams</surname><given-names>JS</given-names></name></person-group><article-title>The pharmacology of vitamin D</article-title><source>Vitamin D</source><year>2011</year><edition>3</edition><publisher-loc>Amsterdam</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>1058</fpage><lpage>61</lpage></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>EFSA Panel on Dietetic Products Nutrition and Allergies (NDA)</collab></person-group><article-title>Scientific opinion on the tolerable upper intake level of vitamin D</article-title><source>EFSA J</source><year>2012</year><volume>10</volume><issue>7</issue><fpage>2813</fpage></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieth</surname><given-names>R</given-names></name></person-group><article-title>Vitamin D, toxicity, policy, and science</article-title><source>J Bone Miner Res</source><year>2007</year><volume>22</volume><issue>Suppl 2</issue><fpage>V64</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1359/jbmr.07s221</pub-id><pub-id pub-id-type="pmid">18290725</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-Gonz&#x000e1;lez</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a-Arellano</surname><given-names>A</given-names></name><name><surname>Toledo</surname><given-names>E</given-names></name><name><surname>Salas-Salvad&#x000f3;</surname><given-names>J</given-names></name><name><surname>Buil-Cosiales</surname><given-names>P</given-names></name><name><surname>Corella</surname><given-names>D</given-names></name><etal/></person-group><article-title>A 14-item Mediterranean diet assessment tool and obesity indexes among high-risk subjects: the PREDIMED trial</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>8</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0043134</pub-id><pub-id pub-id-type="pmid">22905215</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyle</surname><given-names>UG</given-names></name><name><surname>Bosaeus</surname><given-names>I</given-names></name><name><surname>De Lorenzo</surname><given-names>AD</given-names></name><name><surname>Deurenberg</surname><given-names>P</given-names></name><name><surname>Elia</surname><given-names>M</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Bioelectrical impedance analysis&#x02014;part I: review of principles and methods</article-title><source>Clin Nutr</source><year>2004</year><volume>23</volume><issue>5</issue><fpage>1226</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2004.06.004</pub-id><pub-id pub-id-type="pmid">15380917</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarowitz</surname><given-names>BJ</given-names></name><name><surname>Pilla</surname><given-names>AM</given-names></name></person-group><article-title>Bioelectrical impedance in clinical practice</article-title><source>DICP</source><year>1989</year><volume>23</volume><issue>7&#x02013;8</issue><fpage>548</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">2669371</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Ward</surname><given-names>CH</given-names></name><name><surname>Mendelson</surname><given-names>M</given-names></name><name><surname>Mock</surname><given-names>J</given-names></name><name><surname>Erbaugh</surname><given-names>J</given-names></name></person-group><article-title>An inventory for measuring depression</article-title><source>Arch Gen Psychiatry</source><year>1961</year><volume>4</volume><fpage>561</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1961.01710120031004</pub-id><pub-id pub-id-type="pmid">13688369</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Altst&#x000f6;tter-Gleich</surname><given-names>C</given-names></name><name><surname>Hinz</surname><given-names>A</given-names></name><name><surname>Maes</surname><given-names>J</given-names></name><name><surname>Br&#x000e4;hler</surname><given-names>E</given-names></name></person-group><article-title>Normwerte f&#x000fc;r das Vereinfachte Beck-Depressions-Inventar (BDI-V) in der Allgemeinbev&#x000f6;lkerung</article-title><source>Diagnostica</source><year>2006</year><volume>52</volume><issue>2</issue><fpage>51</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1026/0012-1924.52.2.51</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilone</surname><given-names>V</given-names></name><name><surname>Mozzi</surname><given-names>E</given-names></name><name><surname>Schettino</surname><given-names>AM</given-names></name><name><surname>Furbetta</surname><given-names>F</given-names></name><name><surname>Di Maro</surname><given-names>A</given-names></name><name><surname>Giardiello</surname><given-names>C</given-names></name><etal/></person-group><article-title>Improvement in health-related quality of life in first year after laparoscopic adjustable gastric banding</article-title><source>Surg Obes Relat Dis</source><year>2012</year><volume>8</volume><issue>3</issue><fpage>260</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.soard.2011.12.012</pub-id><pub-id pub-id-type="pmid">22398112</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolotkin</surname><given-names>RL</given-names></name><name><surname>Crosby</surname><given-names>RD</given-names></name><name><surname>Gress</surname><given-names>RE</given-names></name><name><surname>Hunt</surname><given-names>SC</given-names></name><name><surname>Adams</surname><given-names>TD</given-names></name></person-group><article-title>Two-year changes in health-related quality of life in gastric bypass patients compared with severely obese controls</article-title><source>Surg Obes Relat Dis</source><year>2009</year><volume>5</volume><issue>2</issue><fpage>250</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.soard.2009.01.009</pub-id><pub-id pub-id-type="pmid">19306822</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathus-Vliegen</surname><given-names>EM</given-names></name><name><surname>de Wit</surname><given-names>LT</given-names></name></person-group><article-title>Health-related quality of life after gastric banding</article-title><source>Br J Surg</source><year>2007</year><volume>94</volume><issue>4</issue><fpage>457</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1002/bjs.5607</pub-id><pub-id pub-id-type="pmid">17310505</pub-id></element-citation></ref></ref-list></back></article>